1 Mutations in ZBTB20 in individuals with persistent stuttering

Carlos E Frigerio Domingues¹⁺, Muhammad Hashim Raza^{1+^}, Tae-Un Han^{1#}, Terra Barnes², Philip Shaw³, Gustavo Sudre³, Sheikh Riazuddin⁴, Robert J. Morell⁵, Dennis Dravna^{1*} 1. Laboratory of Communication Disorders, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, MD 20892 2. Department of Neuroscience, School of Medicine, Washington University in St. Louis, MO 3. Neurobehavioral Clinical Research Section, National Human Genome Research Institute, National Institutes of Health, Bldg. 31, Bethesda MD 20892 4. Allama Iqbal Medical College, University of Health Sciences, Lahore, Pakistan 5. Genomics and Computational Biology Core, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, MD 20892 + These authors contributed equally to this research # Current address: Molecular Neurogenetics Section, National Human Genome Research Institute, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, MD 20892 % Current address: Utah Center for Genetic Discovery, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, UT 84112 * To whom correspondence should be addressed at: NIDCD/National Institutes of Health Porter Neuroscience Research Center 35A Convent Drive, Bethesda, MD 20892 Tel. 301-221-4392 drayna@nidcd.nih.gov ORCID 0000-0002-1730-4532 Key words: Stuttering, Genetics, ZBTB20, Astrocytes

- 1 Abstract
- 2

3 Background: Previous studies identified a strong linkage signal for non-syndromic persistent

4 developmental stuttering on chromosome 3q13.2-3q13.33 in a large consanguineous family. To identify

5 the causative genetic variant at this locus, including we performed further analysis, including whole

6 exome, whole genome, and targeting Sanger sequencing.

7 Results: We identified a homozygous rare c.2155G>A variant in ZBTB20 in individuals who stutter. This 8 mutation encodes Isoleucine in place of a highly conserved Valine at amino acid position 719 in ZBTB20 9 that co-segregates (LOD = 4.23) with stuttering under a model of recessive inheritance with reduced 10 penetrance in this family. Coding variants in this gene were significantly more frequent in a multiethnic 11 cohort of unrelated individuals who stutter than in individuals in large population databases comprised of 12 our normal control subjects and gnomAD database subjects matched for ethnicity. ZBTB20 encodes a 13 zinc-finger transcription factor, and luciferase reporter constructs using genes known to be regulated by 14 ZBTB20 showed that the Ile719 mutant form of the protein displays altered transcriptional regulation in 15 *vitro*. Although homozygosity for mutations in *ZBTB20* has not previously been observed, dominant 16 mutations in ZBTB20 have been reported in Primrose syndrome, a rare Mendelian dominant disorder 17 characterized by tall stature, developmental delay, dysgenesis of the corpus callosum, but generally not 18 speech disorders. Clinical re-examination of the affected family members ten years after their original 19 ascertainment revealed only some suggestive signs associated with Primrose syndrome.

Conclusions: Our findings support variants in *ZBTB20* as a cause of stuttering in a large family, and
rarely in the wider population. Previous studies in mice have demonstrated that *Zbtb20* is required for the
development of astrocytes, a brain cell type previously implicated in an animal model of stuttering. Our
findings support our hypothesis that astrocyte pathology is involved in this disorder. Our findings also
broaden the medical genetic view of disorders of *ZBTB20*, and demonstrate that individuals carrying

a homozygous mutation in this gene can be viable, and that they can primarily display persistent
 developmental stuttering.

3 Introduction

4 Stuttering is a common neurodevelopmental speech disorder that affects the fluency of speech, 5 and is characterized by repetitions and prolongations of speech sounds, and by silent interruptions in the 6 flow of speech known as blocks [1,2]. Twin and adoption studies indicate a high heritability for this 7 disorder [3], however Mendelian segregation does not typically occur [4] and stuttering is considered to 8 be a complex genetic disorder. Linkage studies in consanguineous and polygamous families have 9 identified a number of loci that display strong linkage to this disorder [5,6,7,8,9], and causative genes for 10 stuttering have been identified at a number of these loci [10,11]. The products of the genes identified thus 11 far all physically interact and participate in functions important to intracellular trafficking. Animal studies 12 aimed at elucidating the cellular and anatomic neuropathology caused by these mutations have recently 13 revealed deficits in vocalization and abnormalities in astrocytes, particularly in the corpus callosum 14 [12,13].

15 We have previously reported a large consanguineous family in which many members are affected 16 by persistent neurodevelopmental stuttering. Linkage analysis identified significant linkage on 17 chromosome 3 under an autosomal recessive model with reduced penetrance [8]. Here we have performed 18 additional linkage analyses as well as whole exome, whole genome, and Sanger sequencing, which 19 revealed a unique rare homozygous coding variant in ZBTB20 (MIM: 606025) that co-segregates with 20 stuttering in this family. Although no individuals with homozygous mutations in ZBTB20 have previously 21 been observed, heterozygous mutations have been associated with Primrose syndrome, a rare multisystem 22 developmental disorder [14, 15, 16, 17, 18, 19, 20, 21, 22, 23].

ZBTB20, also known as *DPZF* [24], *HOF* [25], or *ZNF288* is a member of the POK (POZ and
 Krüppel) family of transcription factors. We sought to determine if this variant exerted a functional effect
 on transcription using a luciferase reporter construct in transfected cells. We also performed additional

1 clinical evaluations of the affected subjects in this family, and constructed and tested ultrasonic

2 vocalizations in a knock-in mouse line that carries this mutation.

3 **Results**

4 Stuttering in Family PKST77

5 Consanguineous family PKST77 has been previous described [8]. Speech abnormalities in all five 6 affected subjects were consistent with typical, non-syndromic persistent developmental stuttering. Based 7 on our subsequent genetic findings, family members were re-evaluated 10 years after their initial 8 enrollment. Clinical examinations of four available affected family members were performed at the 9 Allama Iqbal Medical College, Lahore, Pakistan, and included assessment of medical history, physical 10 examination, neurological evaluation. Brain MRI scans performed in Pakistan were analyzed in the

11 Neurobehavioral Clinical Research Section, National Human Genome Research Institute.

12 Identification of variants in *ZBTB20*

13 The pedigree of Family PKST77 is shown in Figure 1A. This family displays highly significant 14 genetic linkage between persistent stuttering and markers on chromosome 3q [8]. We re-investigated the 15 previously reported linkage using a genome-wide SNP linkage scan under a model of recessive 16 inheritance with reduced penetrance [8], which confirmed significant linkage scores in this region and nowhere else across the genome. As previously observed with lower density markers, assignment of 17 18 precise linkage boundaries was limited by instances of apparent non-Mendelian segregation, consistent 19 with the accepted nature of stuttering as a complex trait. Whole-genome sequencing was performed in 20 16 individuals (III-13, III-17, III-21, III-22, IV-23, IV-24, IV-25, IV-26, IV-27, IV-28, IV-29, IV-30, IV-21 31, IV-32, IV-33, IV-34) within this family. The whole-genome sequencing quality control followed the 22 minimum standards requirements established by The American Genome Center at Uniformed Service 23 University, with at least a minimum 30X Illumina coverage, 75% Q30 scores, and 100 gigabases of 24 sequence produced per sample. The analysis identified a mean of 3,824,970 SNVs (range 3,745,519 -25 3,932,504 variants) and a mean of 1,023,407.56 indels (range 998,694 – 1,051,753 indels) (Suppl.1.1).

1	Once annotated, all variants underwent a bioinformatics sorting analysis as follows. First, variants
2	not on chromosome 3 were eliminated, leaving 12,283 variants ($SNPs = 10,181$; Indels = 2,102). Next,
3	variants residing outside the region of significant linkage (11,925 variants) were excluded, leaving a total
4	of 358 variants, all residing withing the previously demonstrated linkage region. Many of these occurred
5	commonly (allele frequency \geq 0.01) in gnomAD v2.1 (Genome Aggregation Database), the 1000
6	Genomes phase 3 dataset, or in the NHLBI ESP6400 dataset. These were eliminated from consideration,
7	and variants with minor allele frequency (MAF) < 0.01 in at least one of these databases were considered
8	further. Of the remaining 41 variants, we focused on the 17 coding variants (15 nonsynonymous, 1
9	frameshift deletion, and 1 stop gain, Table 1), based on the hypothesis that the causative allele in PKST77
10	could be a coding allele of large effect. Only one of these 17 rare variants co-segregated with the disorder
11	under the expected recessive model observed within the family. The variant (c.2155G>A) was in ZBTB20
12	(GenBank: NM_001164342). It occurs at the beginning of exon 5 and is predicted to cause a valine-to-
13	isoleucine substitution (p.Val719Ile), and the location is illustrated in Figure 2. The wild-type valine is
14	conserved across all vertebrates with the exception of coelacanth (Latimeria chalumnae), which carries a
15	phenylamine at this position (Figure 1C and Suppl.1.2). The Val719Ile change is predicted to be disease
16	causing (score:29) by Mutation Taster (<u>http://www.mutationtaster.org/</u>); probably damaging (score:
17	0.999) by PolyPhen-2 (<u>http://genetics.bwh.harvard.edu/pph2/</u>); and tolerated (score: 0.14) by SIFT
18	(https://sift.bii.a-star.edu.sg/).
19	In all family members previously analyzed with whole genome sequencing, the presence of the
20	homozygous variant c.2155G>A in ZBTB20 was confirmed by Sanger sequencing as shown in Figure 1B.
21	In addition, we performed dideoxy sequencing in five additional unaffected members. Across the
22	individuals with fully confirmed genotype data, homozygosity for the Val719Ile variant co-segregates
23	with persistent stuttering.
24	This mutation is rare. It is present in 22/141,456 individuals in the gnomAD Database (v.2.1.1),

and all 22 of these individuals are heterozygous. We note that the individuals in the gnomAD database are

1 (https://gnomad.broadinstitute.org/variant/rs779910215?dataset=gnomad r2 1). A total of 13 other 2 missense variants were found in gnomAD, all present as heterozygotes. This indicates that the affected individuals in PKST77 are the only known individuals homozygous for a coding mutation in ZBTB20. 3 4 We also analyzed our custom-built Communication Exome Database (CED) (N = 1,941 unrelated 5 individuals), sorting for coding variants among stuttering individuals in different cohort populations (N =6 1,074 individuals) and matched controls (N = 867 individuals). No occurrences of the ZBTB20 7 c.2155G>A variant were identified. 8 To estimate the contribution of mutations in *ZBTB20* to stuttering overall, we performed a burden 9 test that compared the rate of rare variants in affected and control individuals. Although the frequency of 10 ZBTB20 coding variants in our combined case groups (66/1,074) was nominally higher than that in the 11 combined controls (41/867), the difference in frequency between cases and controls did not reach 12 statistical significance in any of our population-specific case/control subgroups (Suppl.1.3). We also 13 compared the frequency of rare coding variants in our stuttering cohort (2,148 chromosomes) with that in 14 the general population represented in the gnomAD v.2.1 dataset, (282,912 chromosomes), which likely 15 contains both unaffected and affected individuals (https://gnomad.broadinstitute.org/faq#what-16 populations-are-represented-in-the-gnomad-data). Here, the frequency of rare ZBTB20 variants in our 17 stuttering group was higher overall. We observed more variants in total in our combined stuttering group, 18 which is highly ethnically diverse (88 alleles/2,148 total alleles) than in an ethnically diverse gnomAD 19 population containing similar proportions of European, Asian, and African individuals (5,450 alleles/282,912 total alleles, Chi-square = 52,716, p = 3.85×10^{-13}). These data indicate that rare coding 20 21 variants of all types in ZBTB20 are elevated in the stuttering populations. 22 23 The ZBTB20 Val719Ile mutation suppresses transcriptional repressor activity of ZBTB20 in a human 24 cell. 25

ZBTB20 has been reported to act as a transcriptional repressor for multiple target genes including
alpha fetoprotein (AFP) and inhibitor of kB alpha (IκBα) [26]. To investigate the functional effects of the

1 ZBTB20 Val719Ile mutation on protein activity in human cells, we performed a reporter gene assay 2 using the co-expression of ZBTB20 and luciferase proteins transcribed under control of the AFP 3 promoter. The wildtype and Val719Ile variants of ZBTB20 were transiently over-expressed separately in 4 the human HepG2 cells, along with AFP-luciferase vector, where the measured luciferase activity directly 5 reflected the intracellular activity of ZBTB as a transcriptional repressor. The luciferase activity was 6 reduced about 40% in both the low (20 ng) and high (40 ng) dosage of wildtype ZBTB20 transfection 7 comparing transfection to a control vector. Transfection of the same amount of ZBTB20_Ile719 8 expression vector rendered the transcriptional repressor activity significantly suppressed compared to 9 transfection of wildtype ZBTB20 in both low (p = 0.034) and high dosage (p = 0.0083). The data shown 10 in Figure 3 demonstrates that the ZBTB20 Ile719 is associated with a decrease in the activity of the 11 mutant ZBTB20 protein as a transcriptional repressor in human cells. 12 Ultrasonic mouse vocalizations 13 Animal models of stuttering have been created by generating mouse lines carrying a range of 14 mutations in the GNPTAB gene found in humans who stutter [12, 13]. Such animals displayed altered 15 ultrasonic vocalizations with abnormalities similar in some aspects to those observed in humans who 16 stutter. We used CRISPR-cas to engineer a mouse line carrying the Val719Ile mutation in Zbtb20 [27, 17 Suppl.2.4]. Mice carrying the Zbtb20 Val719Ile variant displayed normal pup isolation call vocalization 18 with respect to amount of vocalization and the spectral frequencies observed. The length of the silent 19 intervals in both the inter-but and intra-bout vocalizations showed a suggestion of increased length 20 compared to those in their genetically wild-type littermates, but this difference was not statistically 21 significant (data not shown). 22 23 Clinical evaluations 24 De novo heterozygous missense variants in ZBTB20 have previously been associated with 25 Primrose syndrome, a rare autosomal dominant disorder that is characterized by a slowly progressive 26 condition associated with tall stature, increased head circumference, atypical facial features, cognitive

1 deficits associated with autism spectrum disorder, and ectopic calcifications [28]. Primrose syndrome 2 patients may subsequently begin to manifest other clinical features including distal muscle atrophy, 3 hearing loss, cataracts, sparse body hair, disturbed glucose metabolism, dense calcification of external 4 ears, and anatomic abnormalities of the corpus callosum. Although Primrose syndrome is clinically 5 consolidated and recognizable in adults, the diagnosis in infants and children is considered difficult [29]. 6 Four affected members of family PKST77 were available ten years after their original enrollment, and 7 they were examined in greater detail (Tables 2 and 3, Suppl.1.4). Many of the most common features of 8 Primrose syndrome, including tall stature and increased head circumference, were absent in these family 9 members. However mild facial dysmorphism and, in some members, mild intellectual disability was 10 noted. 11 Brain MRI scans were available for three family members, one homozygous normal unaffected individual and two homozygous affected individuals. T1-weighted images (176 axial 12 slices, 0.9-mm slice thickness, 256 × 256 acquisition matrix) and diffusion weighted images 13 (TE=89ms, TR=11.1s, 128x128 matrix, slice thickness = 2 mm, gap = 2 mm, 102 directions) 14 were acquired in a 3-T Siemens MAGNETOM Vida scanner. Freesurfer version 7.1.1 15 (https://surfer.nmr.mgh.harvard.edu) and FSL version 6.0.1 (https://fsl.fmrib.ox.ac.uk/) were 16 used to process T1w and DWI data, respectively. Structural characteristics are shown in Table 2. 17 While this sample size was too small to draw statistically significant conclusions, no striking 18 19 differences were observed in the structure of the corpus callosum in these individuals.

In conclusion, the clinical phenotype information available from the members of PKST77 was
limited in our follow-up evaluations. In these evaluations, we noted some individuals with mild facial
dysmorphism and intellectual disability, although these were not consistent across affected individuals.
Both of these signs are observed in Primrose Syndrome, but our limited data precludes a firm conclusion
that this represents a variant form of this disorder.

*

25 Discussion

1 Persistent stuttering has been shown to be highly genetic in origin, and several individual 2 genes that contribute to this disorder have been described [10,11]. However, the genes found 3 thus far appear to account for only a fraction of cases of stuttering, and it is clear that additional 4 genetic factors exist. Data supporting the view that variants in ZBTB20 cause of stuttering comes from 5 four lines of evidence. First, strong evidence for linkage of stuttering to this region has been documented 6 in a large, consanguineous family [8]. Second, homozygous mutations at a highly conserved site in the 7 protein encoded by this gene co-segregate with stuttering under an appropriate model of recessive 8 transmission with reduced penetrance, and no other variants in the linkage region passed our filtering 9 criteria. Third, in a population-based burden test we found a higher frequency of rare variants in this gene 10 in stuttering cases compared to ethnically matched control database groups. Fourth, this gene encodes a 11 transcription factor. The variant in this gene present in the large consanguineous family causes a 12 functional defect in its transcriptional regulatory activity in an *in vitro* luciferase reporter system. In 13 addition to these four lines of evidence, ZBTB20 is known to be a major determinant of astrocyte 14 development in the brain [30, 31]. Studies have identified prominent astrocyte deficits in mice that 15 exhibit stuttering-like vocalization deficits due to a mutation in GNPTAB, a previously identified 16 stuttering gene [13]. Thus, our findings in ZBTB20 may further support a role for astrocyte deficits in 17 humans who stutter.

Primrose syndrome is a dominant disorder, and all patients described to date carry a mutation in just one of their two *ZBTB20* alleles. It is not yet known if these mutations act as dominant negatives or via haploinsufficiency. Given the involvement of ZBTB20 in a range of important developmental processes [30, 31, 32, 33, 34], it is possible that homozygosity for mutations in this gene is generally incompatible with viability. This idea is supported by the lack of individuals homozygous for any coding sequence mutation in *ZBTB20* in the existing gnomAD v.2.1 dataset, representing 141,456 multi-ethnic individuals.

1	We note that, in contrast to the homozygosity for the variant in family PKST77, our population-
2	based burden test identified mostly heterozygous ZBTB20 variants. This was the case for both our
3	stuttering groups and control groups. We suggest that while the unusual homozygosity in family PKST77
4	resulted in identification of a genotype with large effect, other ZBTB20 alleles may exert an effect in a
5	heterozygous state, but discernable only at the population level. It is also noteworthy that stuttering has
6	not been described in Primrose Syndrome to date (https://www.omim.org/entry/259050). We note that
7	the stuttering genes identified thus far had been previously associated with other rare Mendelian medical
8	genetic disorders, none of which had stuttering as a noted feature of their clinical presentation [10, 11,
9	https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Mucolipidoses-Fact-Sheet,
10	https://omim.org/entry/607244]. The reasons for this are not fully understood, but for one of these genes,
11	it has been shown that the mutational spectrum present in stuttering does not overlap with the mutations
12	in this gene seen in the rare medical genetic disorder [35].
13	Zbtb20 is fundamental in brain development and function, and it is expressed in
14	developing hippocampal neurons, as well as in astrocytes in the cerebral cortex and cerebellum
15	[32, 33, 34] where it has been demonstrated to be an essential regulator of astrocyte
16	development. During this development, Zbtb20 is highly expressed in neural precursor cells at
17	late stages of neocortical development, and it is involved in the differentiation and maturation of
18	astrocytes while suppressing the development of neurons [30].
19	Animal models of stuttering have been created by inserting human stuttering mutations
20	into the mouse [12, 13] and such mice display abnormalities in their ultrasonic vocalizations that
21	share similarities with the speech deficits in human who stutter and carry these same mutations.
22	The mice display anomalies in their brain astrocytes, and this pathology is significantly displayed
23	in the corpus callosum [13]. Structural abnormalities of the corpus callosum are a feature of
24	Primrose syndrome [14, 20, 36], and although we did not observe such abnormalities in the

members of family PKST077, the small number of subjects available for evaluation limits this 1 conclusion. It is interesting to note that this gene plays a major role in the development of mammalian 2 3 astrocytes [30], a cell type previously discovered in a mouse model of stuttering caused by another gene 4 [13]. While our findings do not speak to the state of potential astrocyte pathology in the members of 5 family PKST77, they suggest a functional deficit in the transcriptional regulatory function of ZBTB20 in 6 this family. If astrocyte pathology is associated with human stuttering, our findings here would be 7 consistent with this, and should warrant additional investigation of this so-called astrocyte hypothesis in 8 human stuttering. We note these findings implicate astrocyte pathology indirectly, and that previous 9 findings were found with mutations in a different gene (GNPTAB) using a mouse model of stuttering. 10 The present findings in human stuttering, originally based on a mechanistically agnostic linkage study, 11 demonstrate an alteration in function in a transcription factor necessary for astrocyte development.

We suggest that mutations in *ZBTB20* are a relatively rare cause of stuttering, as such mutations were observed in only a small number of unrelated individuals who stutter beyond family PKST077. Nevertheless, we believe these findings open new avenues of research into the neuropathological underpinnings of this enigmatic disorder.

16 Materials and Methods

17 Subjects

All human subjects, including individuals from a consanguineous family (PKST77), with the inclusion diagnosis of non-syndromic persistent stuttering were enrolled with written informed consent under NIH protocol 97-DC-0057 (Genetic studies of stuttering), also reviewed and approved by the IRB of the Centre of Excellence in Molecular Biology, University of the Punjab, as previously described (Raza et al., 2010). All subjects were age 8 and older. Documented neurologically normal control DNA samples (NDPT; N = 460) were obtained from the National Institute of Neurological Disorders and Stroke (NINDS) panels NDPT006, 3 <u>https://www.coriell.org/Search?grid=0&q=ninds&csId=&f_0=NINDS+Repository&f_1=Control</u>

4 $\&f_{2=96+well+plate+of+DNA+samples}$). Our study also included unrelated affected individuals

5 (total N = 1,074) and population-matched control individuals (N = 867), which was made up of

6 Pakistani affected individuals (PKSTR; N = 72) and Pakistani normally fluent controls (PKNR;

7 N = 96), Cameroonian affected (STCR; N = 105) and control (RC; N = 93) individuals, North

8 American affected individuals, including those from our NIH group (NIH; N = 739) and

9 Brazilian affected individuals (BRMII; N = 158) and controls (BRCO; N = 218). Stuttering was

10 diagnosed as previously described [37, 38]. Individuals were classified as affected as previously

11 described [10]. Affected individuals were classified as unrelated by self-report, and no genotypic

12 evidence for the relatedness among these subjects was observed. The identity of all subjects is

13 protected under the privacy and confidentiality guidelines of the National Institutes of Health

14 Institutional Review Board (Protocol 97-DC-0057), and the identities of the subjects are not

15 known outside of the research group.

16 Linkage analysis

Two independent linkage analyses were performed in family PKST77. The first was
described by Raza et al. (2010). The second, newly performed in this study, used the same
subjects, here genotyped at 551,839 SNPs assayed on the Illumina Infinium CoreExome-24 v.1.1
arrays according to manufacturer's protocols. The linkage analysis was performed using
MERLIN 1.1.2. (https://csg.sph.umich.edu/abecasis/Merlin/download/) with parametric and nonparametric models.

23 Whole Exome and Genomic Sequencing

1	Genomic DNA was purified from whole-blood samples using a PAXgene [®] Blood DNA
2	Kit (QIAGEN), or from saliva samples using an Oragene® DNA kit (DNA Genotek Inc.,
3	Canada), according to the manufacturer's protocols. Exome enriched DNA libraries were
4	prepared using Nextera Rapid Capture Exome (Illumina, San Diego, CA, USA) and were
5	sequenced on an Illumina HiSeq1500 with 75 x 75 paired-end reads in 1,941 samples.
6	Additionally, whole-genome libraries were prepared on 16 members of the family PKST77 using
7	an Illumina Nextera TruSeq DNA PCR-free kit and sequenced on an Illumina HiSeq X Ten at
8	The American Genome Center at Uniformed Service University (TAGC-USU,
9	https://www.usuhs.edu/chirp/bioinformatics).
10	
11	Sequence Data Analyses
12	Whole-exome and whole-genome sequence quality control reads were aligned to Genome
13	Reference Consortium Human Build 38 patch release 12 (GRCh38.p12).
14	Bioinformatic pipelines
15	Whole-exome data was analyzed using the bcbio-nextgen germline variant pipeline
16	(https://bcbio-nextgen.readthedocs.io/en/latest/). For variant calling, the "ensemble" vcf file was
17	used, which required that a variant be detected in at least two of the following variant callers:
18	gatk-haplotype, platypus, vascan, freebayes, or Samtools. The complete snakemake pipeline
19	script is provided in the supplement (Suppl.2.1 and Suppl.2.2).
20	Whole-genome data: for genomic alignment was used NovoAlign - Novocraft 3.08.02
21	(http://www.novocraft.com/products/novoalign/), followed by Picard Toolkit 2.9.2
22	(https://broadinstitute.github.io/picard/), the variants were called using Genome Analysis Tool
23	Kit 3.8.0 (GATK) (https://software.broadinstitute.org/gatk/) according to Best Practices

1	Workflow (https://software.broadinstitute.org/gatk/best-practices/) and, called variants were
2	annotated using ANNOVAR, release 2017Jul16.
3	(http://annovar.openbioinformatics.org/en/latest/).
4	
5	Database annotation and variant sort
6	A total of 1,941 samples among unrelated stuttering cases and controls were analyzed in
7	a custom-built Communication Exome Database (CED). This MySQL relational database
8	included metadata on each individual, variants from the corresponding "ensembl.vcf" file, and
9	extensive metadata on each variant including annotations from the Genome Aggregation
10	Database (gnomAD v2.1) (https://gnomad.broadinstitute.org/), 1000 Genomes Project phase 3
11	(http://useast.ensembl.org/Homo_sapiens/Info/Index), National Heart, Lung, and Blood Institute
12	- Exome Sequencing Project (NHLBI-ESP) Exome Variant Server
13	(https://evs.gs.washington.edu/EVS/), Kaviar Project (http://db.systemsbiology.net/kaviar/cgi-
14	pub/Kaviar.pl), dbSNP (https://www.ncbi.nlm.nih.gov/snp/). Variants with minor allele
15	frequency ≥ 0.01 were filtered out. The remaining variants, sorted according to chromosome
16	position, gene function, type of amino acid changed, evolutionary conservation level and clinical
17	information using annotations provided by public databases (including RefSeq
18	[https://www.ncbi.nlm.nih.gov/refseq/], knownGene [http://genome.ucsc.edu/] dbNSFP
19	database, [https://sites.google.com/site/jpopgen/dbNSFP] and ClinVar database
20	[https://www.ncbi.nlm.nih.gov/clinvar/]).
21	Sanger sequencing
22	Sanger sequencing was performed to validate all variants previously identified by whole
23	exome sequencing. Oligos were designed using Primer3 (<u>http://bioinfo.ut.ee/primer3-0.4.0/</u>) and

1	are listed in the supplemental materials (Suppl.2.3). Sanger dideoxy sequencing of all exons and
2	their 40 bp flanking regions was performed using BigDye® Terminator Cycle Sequencing Kit
3	v3.1 (Applied Biosystems, Foster City, CA, USA) with standard manufacturer's protocols.
4	Sequence reactions were resolved on an ABI Genetic Analyzer 3730xl instrument (Applied
5	Biosystems) and the electropherograms were evaluated using DNASTAR [®] Lasergene SeqMan
6	Pro TM (v.13.0.2) (<u>https://www.dnastar.com/software/lasergene/</u>).
7	
8	Construction of ZBTB20 expression vectors
9	ZBTB20 expression vector was prepared using OriGene (OriGene Tech. Inc., MD),
10	TrueORF [®] cDNA clone (Cat#: RC228567) (available in: <u>https://www.origene.com/catalog/cdna-</u>
11	clones/expression-plasmids/rc228567/zbtb20-nm_001164342-human-tagged-orf-clone). This
12	vector expresses ZBTB20 human isoform 1 (NM_001164342) under the control of a CMV
13	promoter. The wild type valine at position 719 of ZBTB20 was replaced with isoleucine by
14	introducing a point mutation using QuickChange II Site-Directed Mutagenesis kit (Agilent Tech.
15	Inc., CA). The promoter of alpha fetoprotein (AFP, -2320 to 23 bp) was amplified from genomic
16	DNA of a normal human individual using a KOD Hot Start DNA Polymerase (EMD Millipore
17	Corp., US) with primers of 5'-AAGGTACCTTACTCCTGGTGTAGTCGCATC -3' and 5'-
18	AAAACTCGAGTGGCAGTGGTGGAAGCACAATA -3', which were designed to introduce
19	KpnI and XhoI restriction enzyme sites (underlined) at the 5' and 3' ends of the promoter
20	sequence, respectively. These restriction sites were used in subcloning of the PCR product into
21	pGL4.10[luc2] Firefly Luciferase Vector (Promega Corp., WI).
22	

23 Luciferase reporter assay

1	In 96-well white solid plates microplates, 4×10^4 HepG2 cells were seeded and
2	transiently transfected next day with 100 ng of plasmids which include 40 ng of ZBTB20-
3	expression vector (pCMV6-ZBTB20) or empty expression vector (pCMV6-Entry Tagged
4	Cloning Vector, OriGene Tech. Inc., MD) (Cat#: PS100001), 40 ng of pGL4.10-AFP, and 20 ng
5	of Renilla Luciferase Control Reporter Vector as a transfection efficiency control (pRL-TK,
6	Promega Corp., WI) using Lipofectamine [™] 3000 Transfection Reagent (Thermo Fisher
7	Scientific Inc., CA) according to the manufacturer's instructions. Opti-MEM® Reduced-Serum
8	Medium (Gibco TM) was replaced by Eagle's Minimum Essential Medium (EMEM) (ATCC [®])
9	with 10% fetal bovine serum after 4 hours of transfection. Luciferase activity was measured
10	using the Dual-Glo [®] Luciferase Assay System (Promega Corp., WI) after 27 hours of
11	transfection with Mithras LB940, Multimode Microplate Reader (Berthold Tech. GmbH & Co.,
12	Germany). All experiments were performed with four trials, with four replicates in each trial.
13	
14	Clinical Studies
15	Clinical and Neurological evaluations of the members of family PKST077 were
16	performed at Allama Iqbal Medical Research Institute, Lahore, Pakistan and at the National
17	Human Genome Research Institute, NIH. Brain MRI studies were available from individuals IV-
18	24, IV-26, and IV-27 (Figure 1A).
19	2.10. KI mouse model
20	We used the CRISPR/Cas9 genome editing technology [27] to generate a knock-in mouse
21	model that mimics the mutation founded in the affected members of stuttering family PKST77.

22 (http://www.informatics.jax.org/marker/MGI:1929213), several different crRNAs were designed

1 to target the sequence near to the variant and minimize potential off-target sites. More details are

2 available in the Supplementary material 2.4 (Suppl.2.4).

- 3
- 4 Ultrasound mouse vocalization analysis
- 5 The ultrasonic vocalizations of mice carrying the equivalent of the human Ile719Val
- 6 mutation and their wild type littermates were gathered as previously described [12].

7 Abbreviations used

- 8 NIDCD- National Institute on Deafness and Other Communication Disorders
- 9 ZBTB20- Zinc finger and BTB domain containing, 20
- 10 NHLBI- National Heart Lung and Blood Institute
- 11 CED- Communications Exome Database
- 12 AFP- Alpha feto protein
- 13 I κ B α Inhibitor of kB alpha
- 14 GNPTAB- N-acetylglucosamine-1-phosphate transferase subunits alpha and beta
- 15 CRISPR-cas Clustered Regularly Interspaced Short Palindromic Repeats-Crispr-associated
- 16 protein 9
- 17 IRB- Institutional Review Board
- 18 NINDS- National Institute of Neurological Diseases and Stroke
- 19 PKSTR- Pakistani stuttering affected individuals, unrelated
- 20 PKNR- Pakistani normally fluent controls, unrelated
- 21 STCR- Cameroonian stuttering affected individuals, unrelated
- 22 RC- Cameroonian normal control individuals, unrelated
- 23 BRMII- Brazilian stuttering affected individuals, unrelated

1 BRCO- Brazilian normally fluent control individuals, unrelated

- 2 EMEM- Eagle's Minimum Essential Medium
- 3 KI- Knock-in
- 4

5 Deciar autoris	5	Decl	larati	ions
------------------	---	------	--------	------

6 Ethical approval and consent to participate – Subjects were enrolled with written informed

7 consent under NIH Institutional Review Board-approved Consent # 97-DC-0057 entitled Genetic

8 Studies of Stuttering.

9 **Consent for publication** – Subjects consented to publication without identifying information

10 under NIH Institutional Review Board-approved Consent # 97-DC-0057 entitled Genetic Studies

11 of Stuttering.

12 Availability of Supporting data – Supporting data not presented in the Supplementary materials

13 is available from the communicating author at: <u>drayna@nidcd.nih.gov</u>

14 **Competing Interests** - The authors declare no competing interests.

15 **Funding** - This work was supported in part by the National Institute on Deafness and Other

16 Communication Disorders (NIDCD) Intramural grant # Z01-DC-000047-19, the NIDCD

17 Genomic and Computational Biology Core # Z1C-000086,

18 Author contributions - CFD performed DNA sequencing, and linkage and bioinformatic

19 analyses, MHR ascertained and sampled subjects and performed linkage analyses and DNA

- 20 sequencing, TUH performed luciferase reporter studies, TB performed mouse ultrasonic
- vocalization studies, PS and GS evaluated MRI and other clinical data, SR ascertained subjects

and supervised research in Pakistan, RM oversaw whole exome and whole genome sequencing,

and DD conceived of the study, obtained funding, oversaw human subjects protection, and

1 supervised all aspects of research. All authors contributed to writing and reviewing the

2 manuscript.

3	Acknowledgements - This work used the high performance computational capabilities of the							
4	Biowulf Linux Cluster at the National Institutes of Health, Bethesda, MD							
5	(http://biowulf.nih.gov). We thank Dr. Timothy Holy of Washington University St. Louis for							
6	support of TB, and The Stuttering Foundation, the National Stuttering Association, and Hollins							
7	Communications Research Institute, Roanoke, VA for assistance with subject recruitment.							
8	Authors' information:							
9 10 11	Carlos E Frigerio Domingues ¹⁺ , Muhammad Hashim R Gustavo Sudre ³ , Sheikh Riazuddin ⁴ , Robert J. Morell ⁵ ,	aza ^{1+^,} Tae-Un Han ^{1#} , Terra Barnes ² , Philip Shaw ³ , Dennis Drayna ^{1*}						
12	1. Laboratory of Communication Disorders, National In	nstitute on Deafness and Other Communication						
13	Disorders, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, MD 20892							
14	2. Department of Neuroscience, School of Medicine, Washington University in St. Louis, MO							
15	3. Neurobehavioral Clinical Research Section, National Human Genome Research Institute, National							
16	Institutes of Health, Bldg. 31, Bethesda MD 20892							
17	4. Allama Iqbal Medical College, University of Health Sciences, Lahore, Pakistan							
18	5. Genomics and Computational Biology Core, National Institute on Deafness and Other Communication							
19	Disorders, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, MD 20892							
20	+ These authors contributed equally to this research							
21	# Current address: Molecular Neurogenetics Section, N	lational Human Genome Research Institute,						
22	National Institutes of Health, Porter Neuroscience Rese	earch Center, Bethesda, MD 20892						
23	% Current address: Utah Center for Genetic Discovery,	Eccles Institute of Human Genetics, University of						
24	Utah, Salt Lake City, UT 84112							
25 26 27 28 29 30 31	* To whom correspondence should be addressed at:	NIDCD/National Institutes of Health Porter Neuroscience Research Center 35A Convent Drive, Bethesda, MD 20892 Tel. 301-221-4392 <u>drayna@nidcd.nih.gov</u> ORCID 0000-0002-1730-4532						
32								

References

2	1. American Psychiatric Association & Force, D. S. M. T. (2013). Diagnostic and statistical manual of
3	mental disorders : DSM-5. American Psychiatric Association, Washington, D.C.
4	2. International Classification of Diseases, 10 th Edition (ICD-10), World Health Organization (2013)
5	3. Frigerio-Domingues, C., & Drayna, D. (2017). Genetic contributions to stuttering: the current evidence.
6	Mol Genet Genomic Med, 5(2), 95-102. doi:10.1002/mgg3.276
7	4. Kidd, K. K., Heimbuch, R. C., & Records, M. A. (1981). Vertical transmission of susceptibility to
8	stuttering with sex-modified expression. Proc Natl Acad Sci U S A, 78(1), 606-610.
9	5. Domingues, C. E., Olivera, C. M., Oliveira, B. V., Juste, F. S., Andrade, C. R., Giacheti, C. M., Drayna,
10	D. (2014). A genetic linkage study in Brazil identifies a new locus for persistent developmental
11	stuttering on chromosome 10. Genet Mol Res, 13(1), 2094-2101. doi:10.4238/2014.March.24.13
12	6. Raza, M. H., Amjad, R., Riazuddin, S., & Drayna, D. (2012). Studies in a consanguineous family reveal a
13	novel locus for stuttering on chromosome 16q. Hum Genet, 131(2), 311-313.
14	doi:10.1007/s00439-011-1134-2
15	7. Raza, M. H., Gertz, E. M., Mundorff, J., Lukong, J., Kuster, J., Schaffer, A. A., & Drayna, D. (2013).
16 17	Linkage analysis of a large African family segregating stuttering suggests polygenic inheritance. Hum Genet. 132(4). 385-396. doi:10.1007/s00439-012-1252-5
18	8. Raza, M. H., Riazuddin, S., & Drayna, D. (2010). Identification of an autosomal recessive stuttering
19	locus on chromosome 3g13.2-3g13.33. Hum Genet, 128(4), 461-463. doi:10.1007/s00439-010-
20	0871-y
21	9. Riaz, N., Steinberg, S., Ahmad, J., Pluzhnikov, A., Riazuddin, S., Cox, N. J., & Drayna, D. (2005).
22	Genomewide significant linkage to stuttering on chromosome 12. Am J Hum Genet, 76(4), 647-
23	651. doi:10.1086/429226
24	10. Kang, C., Riazuddin, S., Mundorff, J., Krasnewich, D., Friedman, P., Mullikin, J. C., & Drayna, D. (2010).
25	Mutations in the lysosomal enzyme-targeting pathway and persistent stuttering. N Engl J Med,
26	362(8), 677-685. doi:10.1056/NEJMoa0902630
27	11. Raza, M. H., Mattera, R., Morell, R., Sainz, E., Rahn, R., Gutierrez, J., Drayna, D. (2015a).
28	Association between Rare Variants in AP4E1, a Component of Intracellular Trafficking, and
29	Persistent Stuttering. Am J Hum Genet, 97(5), 715-725. doi:10.1016/j.ajhg.2015.10.007
30	12. Barnes, Terra D., Wozniak, David F., Gutierrez, J., Han, TU., Drayna, D., & Holy, Timothy E. (2016). A
31	Mutation Associated with Stuttering Alters Mouse Pup Ultrasonic Vocalizations. Current Biology,
32	26(8), 1009-1018. doi: <u>http://dx.doi.org/10.1016/j.cub.2016.02.068</u>
33	13. Han, T. U., Root, J., Reyes, L. D., Huchinson, E. B., Hoffmann, J. D., Lee, W. S., Drayna, D. (2019).
34	Human GNPTAB stuttering mutations engineered into mice cause vocalization deficits and
35	astrocyte pathology in the corpus callosum. Proc Natl Acad Sci U S A, 116(35), 17515-17524.
36	doi:10.1073/pnas.1901480116
37	14. Alby, C., Boutaud, L., Bessières, B., Serre, V., Rio, M., Cormier-Daire, V., Thomas, S. (2018). Novel
38	de novo ZBTB20 mutations in three cases with Primrose syndrome and constant corpus callosum
39	anomalies. Am J Med Genet A, 1/6(5), 1091-1098. doi:10.1002/ajmg.a.38684
40	15. Casertano, A., Fontana, P., Hennekam, R. C., Tartaglia, M., Genesio, R., Dieber, T. B., Melis, D.
41	(2017). Alterations in metabolic patterns have a key role in diagnosis and progression of
42	primrose syndrome. Am J Med Genet A, 1/3(7), 1896-1902. doi:10.1002/ajmg.a.38124
43	16. Cleaver, K., Berg, J., Crajt, E., Foster, A., Gibbons, K. J., Hobson, E., Latton-Brown, K. (2019).
44 45	Regining the Primrose synarome phenotype: A study of five patients with 281820 de novo
45	variants and a review of the literature. Am J Med Genet A, 179(3), 344-349.
46	uoi:10.1002/ajmg.a.6102491

17. Cordeddu, V., Redeker, B., Stellacci, E., Jongejan, A., Fragale, A., Bradley, T. E., . . . Hennekam, R. C. 1 2 (2014). Mutations in ZBTB20 cause Primrose syndrome. Nat Genet, 46(8), 815-817. 3 doi:10.1038/ng.3035 4 18. Ferreira, L. D., Borges-Medeiros, R. L., Thies, J., Schnur, R. E., Lam, C., & de Oliveira, J. R. M. (2019). 5 Expansion of the Primrose syndrome phenotype through the comparative analysis of two new 6 case reports with ZBTB20 variants. Am J Med Genet A, 179(11), 2228-2232. 7 doi:10.1002/ajmg.a.61297 8 19. Grímsdóttir, S., Hove, H. B., Kreiborg, S., Ek, J., Johansen, A., Darvann, T. A., & Hermann, N. V. (2019). 9 Novel de novo mutation in ZBTB20 in primrose syndrome in boy with short stature. Clin 10 Dysmorphol, 28(1), 41-45. doi:10.1097/mcd.00000000000244 11 20. Mattioli, F., Piton, A., Gérard, B., Superti-Furga, A., Mandel, J. L., & Unger, S. (2016). Novel de novo 12 mutations in ZBTB20 in Primrose syndrome with congenital hypothyroidism. Am J Med Genet A, 13 170(6), 1626-1629. doi:10.1002/ajmg.a.37645 14 21. Posmyk, R., Leśniewicz, R., Chorgży, M., & Wołczyński, S. (2011). New case of Primrose syndrome 15 with mild intellectual disability. Am J Med Genet A, 155a(11), 2838-2840. 16 doi:10.1002/ajmg.a.34257 17 22. Stellacci, E., Steindl, K., Joset, P., Mercurio, L., Anselmi, M., Cecchetti, S., . . . Rauch, A. (2018). Clinical 18 and functional characterization of two novel ZBTB20 mutations causing Primrose syndrome. 19 Hum Mutat, 39(7), 959-964. doi:10.1002/humu.23546 20 23. Yamamoto-Shimojima, K., Imaizumi, T., Akagawa, H., Kanno, H., & Yamamoto, T. (2020). Primrose 21 syndrome associated with unclassified immunodeficiency and a novel ZBTB20 mutation. Am J 22 Med Genet A, 182(3), 521-526. doi:10.1002/ajmg.a.61432 23 24. Zhang, W., Mi, J., Li, N., Sui, L., Wan, T., Zhang, J., . . . Cao, X. (2001). Identification and 24 characterization of DPZF, a novel human BTB/POZ zinc finger protein sharing homology to BCL-6. 25 Biochem Biophys Res Commun, 282(4), 1067-1073. doi:10.1006/bbrc.2001.4689 26 25. Mitchelmore, C., Kjaerulff, K. M., Pedersen, H. C., Nielsen, J. V., Rasmussen, T. E., Fisker, M. F., . . . 27 Jensen, N. A. (2002). Characterization of two novel nuclear BTB/POZ domain zinc finger isoforms. 28 Association with differentiation of hippocampal neurons, cerebellar granule cells, and macroglia. 29 J Biol Chem, 277(9), 7598-7609. doi:10.1074/jbc.M110023200 30 26. Xie, Z., Zhang, H., Tsai, W., Zhang, Y., Du, Y., Zhong, J., . . . Zhang, W. J. (2008). Zinc finger protein 31 ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci U S 32 A, 105(31), 10859-10864. doi:10.1073/pnas.0800647105 33 27. Henao-Mejia, J., Williams, A., Rongvaux, A., Stein, J., Hughes, C., & Flavell, R. A. (2016). Generation of 34 Genetically Modified Mice Using the CRISPR-Cas9 Genome-Editing System. 2016(2), 35 pdb.prot090704. doi:10.1101/pdb.prot090704 28. Primrose, D. A. (1982). A slowly progressive degenerative condition characterized by mental 36 37 deficiency, wasting of limb musculature and bone abnormalities, including ossification of the 38 pinnae. J Ment Defic Res, 26 (Pt 2), 101-106. doi:10.1111/j.1365-2788.1982.tb00133.x 39 29. Melis, D., Carvalho, D., Barbaro-Dieber, T., Espay, A. J., Gambello, M. J., Gener, B., . . . Hennekam, R. 40 C. (2020). Primrose syndrome: Characterization of the phenotype in 42 patients. Clin Genet, 41 97(6), 890-901. doi:10.1111/cge.13749 42 30. Nagao, M., Ogata, T., Sawada, Y., & Gotoh, Y. (2016). Zbtb20 promotes astrocytogenesis during 43 neocortical development. Nat Commun, 7, 11102. doi:10.1038/ncomms11102 44 31. Medeiros de Araújo J, Barão S, Mateos-White I, Espinosa A, Costa MR, Gil-Sanz C, Müller U. ZBTB20 45 is crucial for the specification of a subset of callosal projection neurons and astrocytes in the mammalian 46 neocortex. Development 2021 Aug 15;148(16):dev196642. doi:10.1242/dev.196642. Epub 2021 Aug 19.

- 32. Nielsen, J. V., Blom, J. B., Noraberg, J., & Jensen, N. A. (2010). Zbtb20-induced CA1 pyramidal neuron 1 2 development and area enlargement in the cerebral midline cortex of mice. Cereb Cortex, 20(8), 3 1904-1914. doi:10.1093/cercor/bhp261 4 33. Nielsen, J. V., Thomassen, M., Møllgård, K., Noraberg, J., & Jensen, N. A. (2014). Zbtb20 defines a 5 hippocampal neuronal identity through direct repression of genes that control projection neuron 6 development in the isocortex. Cereb Cortex, 24(5), 1216-1229. doi:10.1093 7 34. Sakaguchi, H., Kadoshima, T., Soen, M., Narii, N., Ishida, Y., Ohgushi, M., . . . Sasai, Y. (2015). 8 Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-9 derived dorsomedial telencephalic tissue. Nat Commun, 6(1), 8896. doi:10.1038/ncomms9896 10 35. Raza M, Domingues C, Webster R, Sainz E, Paris E, Rahn, R, Gutierrez J, Chow HM, 11 Mundorff J, Kang C, Riaz N, Basra M, Khan S, Riazuddin S, Moretti-Ferreira D, 12 Braun A, and Drayna D. Mucolipidosis Type II/III alpha and non-syndromic stuttering are 13 associated with different variants in the same genes. European Journal of Human Genetics 14 24(4):529-536 (2015b) 15 36. Juven, A., Nambot, S., Piton, A., Jean-Marçais, N., Masurel, A., Callier, P., . . . Faivre, L. (2020). 16 Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus 17 a 3q13.31 microdeletion including ZBTB20. Eur J Hum Genet, 28(8), 1044-1055. 18 doi:10.1038/s41431-020-0582-3 19 37. Riley, G. D. (1994). Stuttering Severity Instrument for Children and Adults - (SSI-3) (3th ed. ed.). 20 Austin: Pro Ed. 21 38. Webster, R. L. (1980). Evolution of a target-based behavioral therapy for stuttering. J Fluency Disord, 22 5(3), 303-320. doi:http://dx.doi.org/10.1016/0094-730X(80)90035-2
- 23 24

25 Competing Interests

26 The authors have no relevant financial or non-financial interests to disclose.

27 Data Availability

- 28 The datasets generated during and/or analysed during the current study are available from the
- 29 corresponding author on reasonable request.
- 30

31 **Figure Captions**

- 32 **Figure 1 A.** Pedigree of stuttering family PKST77. Individuals diagnosed as affected represented by filled
- 33 symbols. wt, wildtype allele; m, mutated allele; wt/wt, homozygote wildtype; wt/m, heterozygote
- 34 mutated; m/m, homozygote mutated **B.** Dideoxy Sanger sequencing traces showing the c.2155G>A
- variant in ZBTB20 in available family members. C. Amino acid alignments across species of the Valine
- 36 719, in bold
- 37 **Figure 2** Chromosome 3 linkage region, structure of *ZBTB20* gene, and mutation location
- **Figure 3** The ZBTB20_Val719lle variant decreases transcriptional repressor activity. Human HepG2 cells
- 39 were co-transfected with the pCMV6-ZBTB20 wild type or Val719lle mutation, and the pGL4.10-AFP
- 40 reporter vector expressing a luciferase gene under control of the AFP promoter (-2320 to +23). A Renilla-
- 41 luciferase vector (pRL-TK) was also co-transfected to control for transfection efficiency. Relative
- 42 expression level was calculated dividing luciferase activity of pCMV6-ZBTB20 by that of pCMV6_Empty

- 1 vector as a mock control. A total of 16 replications in three independent experiments are shown (total n
- 2 = 16, 16). Legend: Wt, wildtype ZBTB20; Error bar shows SEM.*p value = 0.034; **p value = 0.0083







Target: Afp Cell: HepG2



Zbtb20_V719I variant decreases transcriptional repressor activity

Chr	Start	End	rsID	Ref	Alt	Region	Gene name	Туре	Exon	c.DNA position	Amino Acid change
3	112113049	112113049	rs191148598	G	А	exonic	C3orf52	nonsynonymous	Exon 5	c.553G>A	p.E185K
3	112974799	112974801	rs564728039	AAG	-	exonic	CD200R1	nonframeshift deletion	Exon 1	c.57_59del	p.19_20del
3	112991054	112991054	rs565265086	G	А	exonic	GTPBP8	nonsynonymous	Exon 1	c.55G>A	p.V19M
3	114339076	114339076	rs779910215	С	Т	exonic	ZBTB20	nonsynonymous	Exon 5	c.2155G>A*	p.V719
3	119034641	119034641	rs576681103	G	С	UTR5	IGSF11	-	-	-	-
3	119147246	119147246	rs554707851	С	G	exonic	C3orf30	nonsynonymous	Exon 1	c.1057C>G	p.Q353E
3	119732456	119732456	rs773076124	А	G	exonic	MAATS1	nonsynonymous	Exon 9	c.1181A>G	p.Y394C
3	120348820	120348820	rs201718706	G	Т	exonic	LRRC58	nonsynonymous	Exon 1	c.424C>A	p.L142M
3	121476641	121476641	rs not annotated	G	С	exonic	POLQ	nonsynonymous	Exon 20	c.6304C>G	p.Q2102E
3	121923043	121923043	rs753517272	С	Т	exonic;splicing	SLC15A2	stopgain	Exon 9	c.778C>T	p.Q260X
3	122568928	122568928	rs150765058	С	Т	exonic	DTX3L	nonsynonymous	Exon 3	c.839C>T	p.T280
3	123448538	123448538	rs1279127415	С	А	exonic	ADCY5	nonsynonymous	Exon 1	c.8G>T	p.G3V
3	123700313	123700313	Rs1452968448	Т	С	exonic	MYLK	nonsynonymous	Exon 15	c.3155A>G	p.N1052S
3	125091448	125091448	rs762284041	G	А	exonic	SLC12A8	nonsynonymous	Exon 6	c.1315C>T	p.L439F
3	127003384	127003384	rs199693063	G	А	exonic	PLXNA1	nonsynonymous	Exon 3	c.1432G>A	p.V478
3	128910310	128910310	rs765706722	G	А	exonic	ACAD9	nonsynonymous	Exon 8	c.1192C>T	p.P398S
3	128945350	128945350	rs775891329	С	Т	exonic	CFAP92	nonsynonymous	Exon 3	c.617G>A	p.R206H

 Table 1. List of 17 coding variants (MAF < 0.01) under final investigation.</th>

Note: *ZBTB20 variant present in all affected individuals in homozygous state

 Table 2. PKST 077 Clinical evaluation report.

Clinical finds	Patient ID					
Chinical fillus	PKST77-33	PKST77-34	PKST77-24	PKST77-26		
Gender	Male	Male	Male	Male		
Weight (kg)	56	58	50	50		
Head circumference (cm)	55.5	56.0	49.5	48.0		
Height (meters)	1.75	1.75	1.52	1.52		
Developmental Milestones Delayed*						
Copy Sounds (within six months)	+	+	+	-		
Sit without support (within six months)	+	+	+	-		
Like to play with others, especially parents (within six months)	+	+	+	-		
Respond to own name (within six months)	+	+	+	-		
Copy gestures (6-12 months)	+	+	+	-		
Respond to simple spoken requests (6-12 months)	+	+	+	-		
Say "mama" and "dada" (6-12 months)	+	+	+	-		
Pull up to stand (6-12 months)	+	+	+	-		
Say several single words (12-18 months)	+	+	+	-		
Walk alone (12-18 months)	+	+	< 2 years	4 years		
Say sentence with 2 to 4 words (18-24 months)	+	+	+	-		
Follow simple instructions (18-24 months)	+	+	+	-		
Point to things or pictures when they are named (18-24 months)	+	+	+	-		
Carry on a conversation using 2-3 sentences (24-36 months)	+	+	+	-		
Climb well (24-36 months)	+	+	+	-		
Copy friend and adults (like running when other children run) (24-36 months)	+	+	+	-		
Hop and stand on one foot for up to 2 seconds (36-48 months)	+	+	+	-		
Tell stories (36-48 months)	+	+	+	-		
Draw a person with 2 to 4 body parts (36-48 months)	+	+	+	-		
Morphology, neuromuscular and system involvement findings						
Is there history of birth asphyxia?	-	-	-	-		
Skin pigmentation abnormalities	-	-	-	-		

Table 2. PKST 077 Clinical evaluation report. (*continuation*)

		Patient ID					
Chinical finds	PKST77-33	PKST77-34	PKST77-24	PKST77-26			
Morphology, neuromuscular and system involvement findings							
Facial dysmorphic features	+	+	+	$+^{1}$			
Chin abnormalities	n.a.	-	-	Retrognathia			
Motor weakness	-	-	-	-			
Chest abnormalities	-	-	Barrel shaped	-			
Dental abnormalities	-	-	-	Dysplasia			
Ear abnormalities	-	n.a.	-	-			
Eye abnormalities	-	-	-	$+^{2}$			
Balance problems	-	-	-	-			
Can the patient stand without swaying to any side with eyes open and closed?	-	+	+	+			
Can patient walk on a straight line?	-	+	+	-			
Mood	n.a.	n.a.	labile	n.a.			
Family history							
Miscarriages	n.a.	n.a.	-	-			
Intellectual disability	+	+	+	+			
Congenital abnormalities	-	-	-	+			

Notes: * Reference age in months; + present; - absent; n.a. not available; (1) Prominent supraorbital ridges, (2) Bilateral pterygium, left eye divergent squint

PKST77 Family members	Corpus Callosum Volume (mm ³)	Corpus Callosum Fraction Anisotropy (FA, n.u.)
PKST77-24	3652.1	0.36
PKST77-26	4994.3	0.32
PKST77-27	3982.8	0.34

Table 3. Structural characteristics of the Corpus Callosum in members of Pakistani stuttering family PKST077.